INSIGHTS ON UPSTREAM MANUFACTURING
-
![1782739580030]( "High-Yield Cell Therapy Bioproduction")
High-Yield Cell Therapy BioproductionProducing billions of dental pulp stem cells strains static culture and complicates harvest. A closed planar perfusion approach offers another route, with scale-up lessons from one developer.
-
![Intensifying Cell Production Processes Through Real-Time Control]( "Intensifying Cell Production Processes Through Real-Time Control")
Intensifying Cell Production Processes Through Real-Time ControlReal-time lactate readings steering ATF perfusion automatically offer a route to denser, more scalable NK cell cultures while maintaining viability, a contrast with the limits of batch and fed-batch.
-
![GettyImages-1213787059-scientist-in-laboratory-with-flasks-cell-culture]( "High-Yield MSC Expansion At The Forefront Of Cell Therapy Advancement")
High-Yield MSC Expansion At The Forefront Of Cell Therapy AdvancementAs MSC therapies move from autologous to allogeneic use and higher cell doses, the question shifts from efficacy to reliable expansion. See how design, closed handling, and media shape scale-up.
-
![Covid-19, coronavirus-GettyImages-1300948381]( "Subunit Vaccines Suited For The Fight Against COVID-19")
Subunit Vaccines Suited For The Fight Against COVID-19Protein-based vaccines carry established manufacturing and regulatory pathways, plus storage advantages over genetic approaches. Their development still demands real investment in antigen selection, adjuvants, and process tailoring.
-
Accelerating Multispecific Biologics: Overcoming Light Chain Mispairing10/8/2026
Bispecific discovery depends on solving light chain mispairing without a common light chain. Retaining native IgG attributes may shorten the path from lead optimization to stable CHO cell lines.
-
An Automated Cell-Processing Platform For MSC Harvest10/7/2026
Discover closed, automated harvest, formulation, and dispensing of umbilical cord MSCs at commercial scale, with data on viability, recovery, and filling precision, including single runs.
-
A Novel Approach To Eliminate Light Chain Mispairing10/7/2026
Engineering heavy and light chain constant regions can prevent light chain mispairing in bispecifics, letting sequences move from discovery to manufacturable formats without reengineering.
-
Beyond Fed-Batch: Choosing The Right Path To Process Intensification10/6/2026
Upstream intensification options, from concentrated fed-batch to N-stage perfusion, are weighed against organizational objectives, since no single technical strategy suits every framework.
UPSTREAM MANUFACTURING SOLUTIONS
-
![new drugs by genome editing-GettyImages-1407089196]( "Genome Engineering Platforms")
Leverage the latest genome editing technologies and our exclusive innovations for your mammalian cell line engineering project
-
![TARGATT™ RUO Hypo Plus Human iPSC]( "TARGATT™ RUO Hypo Plus Human iPSC")
Eliminating HLA expression limits T-cell recognition but can invite NK-cell attack. A hypoimmune iPSC line pairs B2M and CIITA knockouts with five immune-modulatory knock-ins to address both arms.
-
![RoosterHD-EV]( "Chemically Defined Media System For Scalable Exosome Manufacturing")
A single fed-batch, chemically defined medium carries MSC and fibroblast cultures from seeding through harvest, extending the exosome collection window and avoiding losses at media exchanges and washes.
-
![GettyImages-2193088373-lab]( "New 2X 4,000L Microbial Fermentation Capacity For Your Program Lifecycle")
Two 4,000L fermenters, run singly or in parallel, extend microbial capacity at mid scale, aiming to carry a program from clinical supply through launch and commercial without changing sites.
-
![GettyImages-628978952-microbe-bacteria-microbial]( "Room To Grow: Exploring The Capabilities Of 15,000L Microbial Manufacturing")
Large-scale microbial fermentation raises hard questions about scale-up, primary recovery, and capacity. A 15,000L multi-product setup in Switzerland addresses them within a broader range of cGMP scales, from 70L upward.
